March 30, 2021
IRT gets new data and recalculated parameters
[Moscow – 30.03.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.4.0. IRT represents a Quantitative Systems Pharmacology (QSP) platform of immune system simultaneously being a tool for development of models related to immune system. IRT is based on two main components. On the one hand, it is a fully-fledged database including a wide variety of features covering the immune system. On the other hand, it comprises Navigator that provides intuitive interface to interact with IRT Database. Thus, a modeler can apply calibrated sub-models exported from IRT as building blocks to simplify the model development process.
Now IRT gets a new portion of data and significant upgrade:
IRT is one of InSysBio’s software tools being under constant development and upgrade for both internal and external usage. Its fundamental objective is to facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas.
To learn the full content of Immune Response Template 3.4.0, please visit irt.insysbio.com.
To get demo access to IRT version 3, please click “sign in” or “user account” on the irt.insysbio.com.
To get more information on any tool or leave your feedback, please feel free to contact us: support@insysbio.com
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | October 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Oct 2025 13:23
InSysBio to announce participation in BioTechX Europe 2025 with focus on AI and QSP
InSysBio announces their participation in BioTechX Europe 2025. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, and Igor Goryanin, Professor at University of Edinburgh, will host a roundtable discussion entitled, "Integrating Artificial Intelligence with Quantitative Systems Pharmacology (QSP): Opportunities and Challenges"
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
1.
16 Oct 2025 12:13
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
InSysBio launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data to be added to InSysBio’s CYTOCON or fIVE databases for use in QSP modeling, analysis, or decision-making. The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
|
29
1.
29 Oct 2025 15:08
The project aims at mechanistic PK/RO modeling to predict optimal dose and regimen of BGB-B2033, GPC3 x 4-1BB bispecific antibody
InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with BeOne Medicines, a global oncology company.
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
